Nemluvio Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Nemolizumab

Indications/Uses

Moderate-to-severe atopic dermatitis (AD) in combination w/ topical corticosteroids &/or topical calcineurin inhibitors in adult & adolescent patients ≥12 yr weighing at least 30 kg, who are inadequately controlled by topical therapies & are candidates for systemic therapy. Adults w/ moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.

Dosage/Direction for Use

SC AD Initially 60 mg followed by 30 mg every 4 wk. Maintenance dose after 16 wk of treatment: 30 mg every 8 wk. PN Patient weighing ≥90 kg Initially 60 mg followed by 60 mg every 4 wk, <90 kg Initially 60 mg followed by 30 mg every 4 wk.

Contraindications

Hypersensitivity.

MIMS Class

Other Dermatologicals

ATC Classification

D11AH12 - nemolizumab ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.

Regulatory Classification

POM

Presentation/Packing

Form

Nemluvio powd for soln for inj 30 mg

Packing/Price

(pre-filled pen) 1's; (pre-filled syringe) 1's

Nemluvio

Manufacturer:

Vetter Pharma